We confirmed that a relevant percentage (up to 30%) of newly diagnosed advanced EGFR/ALK negative and PD-L1 < 50% NSCLC patients do not receive a first-line platinum doublet. This evidence concerns the gene EGFR and non-small cell lung carcinoma.